Exchange Agreements in the Biotechnology Industry
527 Contracts & Agreements
- 89bio, Inc. (1 contract)
- ABEONA THERAPEUTICS INC. (2)
- ACCELERON PHARMA INC (6)
- Achaogen, Inc. (2)
- Acorda Therapeutics (1)
- Actinium Pharmaceuticals, Inc. (2)
- Adhera Therapeutics, Inc. (1)
- ADiTx Therapeutics, Inc. (5)
- ADMA BIOLOGICS, INC. (9)
- Advaxis, Inc. (7)
- AGENUS INC (10)
- AgeX Therapeutics, Inc. (1)
- AGIOS PHARMACEUTICALS INC (5)
- AILERON THERAPEUTICS INC (3)
- Aimmune Therapeutics, Inc. (2)
- Akebia Therapeutics, Inc. (1)
- ALBIREO PHARMA, INC. (2)
- Allarity Therapeutics, Inc. (1)
- Alliqua BioMedical, Inc. (2)
- ALNYLAM PHARMACEUTICALS, INC. (2)
- ALPINE IMMUNE SCIENCES, INC. (1)
- Altimmune, Inc. (5)
- Amgen Inc. (5)
- AMICUS THERAPEUTICS, INC. (1)
- AmpliPhi Biosciences Corp (4)
- ANAVEX LIFE SCIENCES CORP. (1)
- Apellis Pharmaceuticals, Inc. (6)
- Applied Therapeutics Inc. (1)
- AQUINOX PHARMACEUTICALS, INC (2)
- Arbutus Biopharma Corp (5)
- ARENA PHARMACEUTICALS INC (1)
- ARROWHEAD PHARMACEUTICALS, INC. (7)
- Athenex, Inc. (1)
- aTYR PHARMA INC (1)
- AVEO PHARMACEUTICALS INC (2)
- BeiGene, Ltd. (9)
- BICYCLE THERAPEUTICS Ltd (2)
- BioCardia, Inc. (1)
- BIOCRYST PHARMACEUTICALS INC (2)
- Biohaven Pharmaceutical Holding Co Ltd. (1)
- BioNexus Gene Lab Coporation (2)
- BioRestorative Therapies, Inc. (8)
- BIOTIME INC (2)
- BIOXYTRAN, INC (1)
- Blue Water Vaccines Inc. (1)
- BRAINSTORM CELL THERAPEUTICS INC. (2)
- CareDx, Inc. (1)
- CASI Pharmaceuticals, Inc. (4)
- CATALYST BIOSCIENCES, INC. (1)
- Cell Source, Inc. (2)
- Celldex Therapeutics, Inc. (2)
- Cellectar Biosciences, Inc. (3)
- Celsion CORP (1)
- CEREBAIN BIOTECH CORP. (1)
- Chanticleer Holdings, Inc. (4)
- ChemoCentryx, Inc. (2)
- Cidara Therapeutics, Inc. (1)
- Clovis Oncology, Inc. (2)
- Conatus Pharmaceuticals Inc. (2)
- Corvus Pharmaceuticals, Inc. (1)
- CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (1)
- CTI BIOPHARMA CORP (6)
- Cullinan Oncology, LLC (1)
- CURIS INC (9)
- Cyclacel Pharmaceuticals, Inc. (2)
- Day One Biopharmaceuticals Holding Co LLC (1)
- DelMar Pharmaceuticals, Inc. (2)
- Dermavant Sciences Ltd (1)
- Digital Development Partners, Inc. (6)
- DYNAVAX TECHNOLOGIES CORP (1)
- Edge Therapeutics, Inc. (2)
- Emergent BioSolutions Inc. (5)
- Enanta Pharmaceuticals, Inc. (7)
- ENDONOVO THERAPEUTICS, INC. (2)
- Enochian Biosciences Inc (1)
- ENZOLYTICS INC (1)
- ENZON PHARMACEUTICALS, INC. (1)
- Epizyme, Inc. (2)
- Esperion Therapeutics, Inc. (1)
- Fibrocell Science, Inc. (1)
- Fortress Biotech, Inc. (2)
- Gain Therapeutics, Inc. (1)
- GALECTIN THERAPEUTICS INC (1)
- Gene Biotherapeutics, Inc. (2)
- GENOCEA BIOSCIENCES, INC. (8)
- GeoVax Labs, Inc. (2)
- GERON CORP (1)
- Greater Cannabis Company, Inc. (3)
- GT Biopharma, Inc. (3)
- HEAT BIOLOGICS, INC. (2)
- HedgePath Pharmaceuticals, Inc. (2)
- HERON THERAPEUTICS, INC. (1)
- HISTOGENICS CORP (1)
- HST Global, Inc. (4)
- iBio, Inc. (1)
- IMMUNE PHARMACEUTICALS INC (2)
- Immune Therapeutics, Inc. (2)
- ImmunoCellular Therapeutics, Ltd. (4)
- IMMUNOGEN INC (3)
- IMMUNOMEDICS INC (2)
- INFINITY PHARMACEUTICALS, INC. (4)
- INOVIO PHARMACEUTICALS, INC. (1)
- INSMED Inc (3)
- Inspyr Therapeutics, Inc. (2)
- INTERCEPT PHARMACEUTICALS, INC. (6)
- International Stem Cell CORP (3)
- Invitae Corp (2)
- IOVANCE BIOTHERAPEUTICS, INC. (8)
- Kadmon Holdings, Inc. (1)
- Karyopharm Therapeutics Inc. (1)
- Kindred Biosciences, Inc. (1)
- Kiromic Biopharma, Inc. (2)
- LA JOLLA PHARMACEUTICAL CO (1)
- Ligand Pharmaceuticals Incorporated (1)
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. (1)
- MACROGENICS INC (14)
- MARIZYME INC (6)
- MATEON THERAPEUTICS INC (1)
- MERRIMACK PHARMACEUTICALS INC (3)
- Mersana Therapeutics, Inc. (1)
- MiMedx Group, Inc. (2)
- MIRAGEN THERAPEUTICS, INC. (2)
- Molecular Templates, Inc. (1)
- Momenta Pharmaceuticals, Inc. (3)
- Monte Rosa Therapeutics, Inc. (2)
- NANOVIRICIDES, INC. (3)
- NAVIDEA BIOPHARMACEUTICALS, INC. (6)
- NextCure, Inc. (8)
- NORTHWEST BIOTHERAPEUTICS INC (2)
- NOVAVAX INC (13)
- Novus Therapeutics, Inc. (5)
- Nuo Therapeutics, Inc. (3)
- OncBioMune Pharmaceuticals, Inc (4)
- ONCOSEC MEDICAL Inc (1)
- OPGEN INC (3)
- Ophthotech Corp. (3)
- Opko Health, Inc. (3)
- ORAGENICS INC (1)
- Organicell Regenerative Medicine, Inc. (3)
- Organogenesis Holdings Inc. (1)
- Orgenesis Inc. (4)
- Outlook Therapeutics, Inc. (3)
- Ovid Therapeutics Inc. (1)
- PDL BIOPHARMA, INC. (7)
- PIERIS PHARMACEUTICALS, INC. (4)
- POLARITYTE, INC. (6)
- PREDICTIVE TECHNOLOGY GROUP, INC. (1)
- PREMIER BIOMEDICAL INC (3)
- PROGENITY, INC. (3)
- ProMIS Neurosciences Inc. (1)
- Propanc Biopharma, Inc. (1)
- Protagenic Therapeutics, Inc. (2)
- Protagonist Therapeutics, Inc (1)
- Protalix BioTherapeutics, Inc. (3)
- PTC THERAPEUTICS, INC. (3)
- RECURSION PHARMACEUTICALS, INC. (4)
- Rezolute, Inc. (2)
- RITTER PHARMACEUTICALS INC (1)
- ROCKET PHARMACEUTICALS, INC. (1)
- Sage Therapeutics, Inc. (4)
- Sarepta Therapeutics, Inc. (1)
- SELECTA BIOSCIENCES INC (1)
- SELLAS Life Sciences Group, Inc. (1)
- Sesen Bio, Inc. (2)
- Social Capital Suvretta Holdings Corp. III (1)
- Sorrento Therapeutics, Inc. (2)
- Spectrum Pharmaceuticals, Inc. (6)
- Spero Therapeutics, Inc. (1)
- SPHERIX INC (2)
- Spring Bank Pharmaceuticals, Inc. (2)
- Stellar Biotechnologies, Inc. (1)
- Summit Therapeutics Inc. (1)
- Sun BioPharma, Inc. (1)
- Syndax Pharmaceuticals Inc (1)
- Synthetic Biologics, Inc. (1)
- TG THERAPEUTICS, INC. (3)
- Tonix Pharmaceuticals Holding Corp. (1)
- TYME TECHNOLOGIES, INC. (1)
- Unicycive Therapeutics, Inc. (1)
- United Therapeutics Corp (1)
- USA EQUITIES CORP. (1)
- VACCINEX, INC. (2)
- Vaxart, Inc. (1)
- Verastem, Inc. (8)
- Vericel Corp (1)
- Vertex Pharmaceuticals Inc (4)
- VistaGen Therapeutics, Inc. (3)
- VITAL THERAPIES INC (1)
- VITRO DIAGNOSTICS INC (1)
- vTv Therapeutics Inc. (2)
- WINDTREE THERAPEUTICS INC (2)
- Xenetic Biosciences, Inc. (1)
- Xenon Pharmaceuticals Inc. (1)
- XOMA Corp (11)
- YIELD10 BIOSCIENCE, INC. (1)
- ZAFGEN, INC. (2)
- Zymeworks Inc. (2)
- Form of Exchange Agreement, dated March 13, 2024, by and between Unicycive Therapeutics, Inc. and the purchasers named therein (Unicycive Therapeutics, Inc., Filed With SEC on March 14, 2024)
- Form of Securities Exchange Agreement (Rezolute, Inc., Filed With SEC on March 14, 2024)
- Form of Note Exchange Agreement, dated March 8, 2024, between the Company and the holder named therein (PROGENITY, INC., Filed With SEC on March 11, 2024)
- Exchange and Termination Agreement, by and between the Company and affiliates of Deerfield Management Company, L.P., effective upon January 24, 2024 (WINDTREE THERAPEUTICS INC, Filed With SEC on January 25, 2024)
- Exchange Agreement, dated December 28, 2023 by and between the Company and the holders signatory thereto (ADiTx Therapeutics, Inc., Filed With SEC on January 2, 2024)
- Exchange Agreement, dated December 22, 2023 by and between the Company and the holders signatory thereto (ADiTx Therapeutics, Inc., Filed With SEC on December 26, 2023)
- Share Exchange Agreement, dated December 15, 2023, by and among Onconetix, Proteomedix AG, Thomas Meier and the Sellers (Blue Water Vaccines Inc., Filed With SEC on December 21, 2023)
- Form of Note Exchange Agreement, dated December 18, 2023, between the Company and the holders named therein (PROGENITY, INC., Filed With SEC on December 18, 2023)
- Share Exchange Agreement between the Company and holders of Series 1 Preferred Shares dated December 4, 2023 (ProMIS Neurosciences Inc., Filed With SEC on December 8, 2023)
- Assignment and Exchange Agreement (Adhera Therapeutics, Inc., Filed With SEC on November 29, 2023)
- Form of Cancellation and Exchange Agreement between Marizyme, Inc. and the creditor party thereto, dated as of November 20, 2023 (MARIZYME INC, Filed With SEC on November 21, 2023)
- Exchange Agreement, dated as of October 12, 2023, between Applied Therapeutics, Inc. and Venrock Healthcare Capital Partners EG, L.P., Venrock Healthcare Capital Partners III,... (Applied Therapeutics Inc., Filed With SEC on October 13, 2023)
- Convertible Notes Exchange Agreement for Common Stock and Warrants, dated September 18, 2023, by and among, the Company, Athyrium Opportunities III Acquisition LP and Athyrium... (PROGENITY, INC., Filed With SEC on September 19, 2023)
- Cancellation and Exchange Agreement between Marizyme, Inc. and Frank Maresca, dated as of August 30, 2023 (MARIZYME INC, Filed With SEC on September 5, 2023)
- Deferred Expense Exchange Agreement between the Registrant and TheraCour effective July 19, 2023 (NANOVIRICIDES, INC., Filed With SEC on September 1, 2023)
- Form of Exchange Agreement (Invitae Corp, Filed With SEC on August 23, 2023)
- Exchange Agreement, dated July 21, 2023, between AgeX Therapeutics, Inc. and Juvenescence Limited (AgeX Therapeutics, Inc., Filed With SEC on July 21, 2023)
- Form of Exchange Agreement dated as of July 18, 2023 between the Company and the holder of the Exchange Securities (Kiromic Biopharma, Inc., Filed With SEC on July 19, 2023)
- Share Exchange Agreement between BioNexus and Chemrex (BioNexus Gene Lab Coporation, Filed With SEC on July 17, 2023)
- Stock Exchange Agreement dated as of June 1, 2023 between Navidea Biopharmaceuticals, Inc. and John K. Scott, Jr (NAVIDEA BIOPHARMACEUTICALS, INC., Filed With SEC on June 5, 2023)
- Cancellation and Exchange Agreement between Marizyme, Inc. and Frank Maresca, dated as of May 30, 2023 (MARIZYME INC, Filed With SEC on June 5, 2023)
- Cancellation and Exchange Agreement between Marizyme, Inc. and Walleye Opportunities Master Fund Ltd, dated as of May 30, 2023 (MARIZYME INC, Filed With SEC on June 5, 2023)
- Cancellation and Exchange Agreement between Marizyme, Inc. and Hexin Global Ltd., dated as of May 30, 2023 (MARIZYME INC, Filed With SEC on June 5, 2023)
- Exchange Agreement, dated May 1, 2023, by and among ImmunoGen, Inc. and RA Capital Healthcare Fund, L.P (IMMUNOGEN INC, Filed With SEC on May 2, 2023)
- Modification and Exchange Agreement (Allarity Therapeutics, Inc., Filed With SEC on April 25, 2023)
- Form of Exchange Agreement dated as of March 28, 2023 between the Company and the holder of the Exchange Securities (Kiromic Biopharma, Inc., Filed With SEC on March 31, 2023)
- Form of Exchange Agreement (Sarepta Therapeutics, Inc., Filed With SEC on March 3, 2023)
- Employment Agreement, effective as of February 28, 2023, by and between the Company and Kevin G. Shaw (Exhibits and schedules have been omitted pursuant to Item 601 of Regulation... (NextCure, Inc., Filed With SEC on March 2, 2023)
- Fifth Amendment to Lease Agreement, dated November 28, 2022, by and between the Company and ARE-8000/9000/10000 Virginia Manor, LLC. (Exhibits and schedules have been omitted... (NextCure, Inc., Filed With SEC on March 2, 2023)
- Third Amendment to License Agreement and SRA, dated as of September 14, 2022, by and between the Company and Yale University. (Exhibits and schedules have been omitted pursuant to... (NextCure, Inc., Filed With SEC on March 2, 2023)
- Fourth Amendment to Lease Agreement, dated June 10, 2022, by and between the Company and ARE-8000/9000/10000 Virginia Manor, LLC. (Exhibits and schedules have been omitted... (NextCure, Inc., Filed With SEC on March 2, 2023)
- Form of Purchase and Exchange Agreement (Invitae Corp, Filed With SEC on March 1, 2023)
- Exchange Agreement, dated January 17, 2023, by and among Cullinan Oncology, Inc. and the Stockholders named therein (Cullinan Oncology, LLC, Filed With SEC on January 19, 2023)
- Exchange Agreement, dated November 4, 2022, by and among Verastem, Inc. and the Stockholders named therein (Verastem, Inc., Filed With SEC on November 7, 2022)
- Agreement and Plan of Exchange, dated August 1, 2021, by and among Infinivive MD, LLC, Jack Zamora, its Sole Member, and the Registrant (VITRO DIAGNOSTICS INC, Filed With SEC on September 9, 2022)
- Restated and Amended Transaction Agreement, dated August 18, 2022, by and among Zymeworks, Parent, Callco, and ExchangeCo (Zymeworks Inc., Filed With SEC on August 19, 2022)
- Form of Exchange Agreement for the 2026 Notes (INTERCEPT PHARMACEUTICALS, INC., Filed With SEC on August 19, 2022)
- Securities Exchange Agreement between the Company and Astonia LLC (Digital Development Partners, Inc., Filed With SEC on August 15, 2022)
- Securities Exchange Agreement between the Company and EF2T, Inc (Digital Development Partners, Inc., Filed With SEC on August 15, 2022)
- Securities Exchange Agreement between the Company and EFT Holdings, Inc (Digital Development Partners, Inc., Filed With SEC on August 15, 2022)